Another study reported TGFβ-dependent alleviation of vascular endothelial dysfunction via the application of the Rho kinase inhibitor Fasudil in vivo and in vitro and the improvement of several FD symptoms in a modified GLA KO mouse model [38]. This evidence concerns the gene TGFB1 and Fabry disease.